Log In
BCIQ
Print this Print this
 

osimertinib (Tagrisso) (AZD9291)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionOral irreversible inhibitor of EGFR-activating mutations and the T790M EGFR resistance mutation
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor kinase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today